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Infection in a joint replacement is a disaster for the
patient and a challenge for both surgeon and micro-
biologist. Extensive efforts are made to minimize the
incidence of infection. It is common practice to
identifY risk factors and to avoid procedures such as
urethral catheterization, in an attempt to guard against
the most common infecting organisms. We report two
cases of prosthesis infection which highlight the
problems of identification and treatment of infection
with enterococci.
Case 1
A 75-year-old man underwent right total knee replace-
ment with cefuroxime prophylaxis (three doses). Pre-
operatively he had no symptoms of prostatism, and
a urine sample showed no significant bacterial growth.
Postoperatively he developed urinary retention, re-
quiring multiple urethral catheterizations, each with
gentamicin cover followed by oral trimethoprim. He
underwent transurethral resection of the prostate 3
weeks after his arthroplasty surgery. Eight months later
he presented with swelling of the right knee and an
abscess on the suture line. This discharged to reveal a
sinus, from which Staphylococcus aureus was cultured.
In contrast, culture of joint fluid obtained by arthro-
centesis grew Enterococcus jaecalis. At revision arthro-
plasty, there was established joint infection. The
prosthesis and cement were removed and a cement
spacer, incorporating gentamicin, ampicillin and
flucloxacillin, was inserted. At operation, superficial
and sinus tract swabs grew S. aureus, E. jaecalis and
Proteus sp., but cultures ofjoint fluid, bone, cement and
joint tissue yielded pure growths of E. jaecalis. The
patient was treated with intravenous flucloxacillin,
ampicillin and gentamicin for 2 weeks, followed by oral
flucloxacillin and amoxycillin for 4 weeks, and the
infection cleared. He is awaiting the second stage of
revision surgery.
Case 2
A 49-year-old woman with severe rheumatoid arthritis
on long-term steroid therapy and azathioprine had
multiple orthopedic procedures over 20 years. These
included bilateral ankle arthrodeses, an osteotomy of
her right tibia and subsequent knee arthroplasty, fusion
of the left knee and bilateral total hip replacements.
Replacement of the right hip was complicated by
recurrent dislocations, requiring open reduction on
two occasions and early revision of the acetabular
component. Eighteen months later she presented
with severe pain in the right hip and was unable to bear
weight on that joint. Radiologic changes were con-
sistent with infection. Joint fluid obtained by arthro-
centesis grew E. jaecalis and skin flora. A two-stage
revision was planned. At surgery the joint was seen to
be grossly infected. Multiple operative cultures grew
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E. faecalis, sensltlve to ampicillin and glycopeptides
(vancomycin and teicoplanin), but expressing high-
level gentamicin resistance. The patient was treated
with a combination of intravenous ampicillin and
teicoplanin (for which in vitro synergy was demon-
strated) for 2 weeks followed by oral amoxycillin plus
intramuscular teicoplanin for 4 weeks. She awaits
assessment for the second stage of her surgery.
These patients demonstrate several of the etiologic
factors which predispose to prosthetic joint infection:
urologic trauma (case 1), rheumatoid arthritis and
postoperative trauma (case 2). Both cases highlight the
need to collect multiple specimens for culture in order
to make the diagnosis and guide antimicrobial therapy.
Enterococci may cause up to 10% of prosthetic joint
infections and are associated with urologic or gastro-
intestinal procedures [1]. Enterococci are inherently
resistant to the usual orthopedic perioperative anti-
biotic prophylaxis regimens. Until recently enterococci
were predictably sensitive in vitro to combinations of
ampicillin or a glycopeptide antibiotic (vancomycin,
teicoplanin) with an aminoglycoside. However, the
presence of high-level gentamicin resistance abolishes
the potential for synergistic use of aminoglycosides [2].
More recently, both acquired ampicillin resistance and
resistance to glycopeptide drugs have emerged in
enterococci, leading to hospital outbreaks of multiply-
resistant organisms [3]. There is currently a need
for novel therapeutic approaches in order to achieve
cidal antimicrobial activity against enterococci. As
nosocomial infections due to these organisms, notably
multiply-resistant E. faecium, increase, we can expect to
encounter more enterococcal joint infections. The
prevention of such infections requires a reconsideration
of antibiotics for prophylaxis and in cement, as high-
lighted in recent correspondence [4], together with
aggressive management of predisposing perioperative
factors.
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Treatment of disseminated Mycobacterium simiae
infection in AIDS
Clin Microbiol lrifect 1997; 3: 265-267
Mycobacterium simiae is a rare cause of human infection.
It is usually considered to be a commensal in the
sputum ofpatients with underlying pulmonary diseases
[1]. Only a small percentage of immunocompetent
patients have had proven clinical disease [2]. In recent
years, M. simiae has been reported as a cause of dis-
seminated infection in five patients with AIDS [3-6].
Two patients were co-infected with the M. avium
(MAl) complex [4,5]. In three cases, M. simiae was the
only microorganism isolated (from blood culture,
sputum and bone marrow), clearly demonstrating
the pathogenic role of M. simiae [3,6]. The choice of
optimal therapy is unclear, and the outcome was poor
in the five cases previously reported [3-6]. We report
a case of disseminated M. simiae infection in a patient
with AIDS, who was succe5.sfully treated with a
combination regimen that comprised clarithromycin,
sparfloxacin and cycloserine.
A 52-year-old caucasian heterosexual man was
found to be HIV positive in 1989. He had a history of
sexual contacts with prostitutes in Burkina Faso. He
had been treated with zidovudine since October 1990
and was asymptomatic. In September 1994, after travel
to Burkina Faso, he presented with fever, diarrhea and
weight loss of 6 kg. His CD4 cell count was 45/mm3 .
CT scans of the thorax and abdomen showed three
right pulmonary parenchymal nodular opacities and
retroperitoneal lymphadenopathy (1 x 2 cm). All other
investigations were negative and no infective agent
was detected in initial tests. He was treated empirically,
for suspected disseminated MAl infection, with
clarithromycin (2000 mg/day), rifabutin (600 mg/day)
and ethambutol (1200 mg/day). Staining of several
sputum specimens revealed acid-fast bacilli. The patient
responded to this therapy within 2 weeks. Culture from
blood, sputum induction and bronchoalveolar lavage
yielded M. simiae (identified by the National Myco-
bacterium Reference Laboratory). Rifabutin was
